@article{article, title = {{SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of Erdafitinib (ERDA) monotherapy and ERDA and Cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC) whose tumours express FGFR gene alterations}}, publisher = {{Elsevier BV}}, url = {{http://dx.doi.org/10.1016/s0302-2838(24)00385-3 }}, year = {{2024}}, month = {{3}}, author = {{Necchi A and Hussain SA and Loriot Y and de Velasco G}}, doi = {{10.1016/s0302-2838(24)00385-3}}, volume = {{85}}, journal = {{European Urology}}, pages = {{S427-S427}}, note = {{Accessed on 2024/12/22}}}